L angerhans cells (LC)
4 represent a subset of dendritic cells (DC) found in the epithelia of skin and mucosae. They express the common DC marker CD1a but can be distinguished from other DC by the presence of intracellular Birbeck granules, containing the C-type lectin Langerin (CD207) (1) , and by their expression of E-cadherin, enabling tight interaction with epithelial cells (2) . LC are long-lived in comparison to other DC subtypes, and recent studies have highlighted the ability of LCprecursors to proliferate in situ (3) . The molecular signals responsible for these characteristics are unclear.
Recent data have suggested that the TNF superfamily molecule receptor activator of NF-B (RANK, TNFRSF11a) and its ligand, RANKL (TNFSF11), play a key role in the regulation of several DC functions including enhancement of their capacity to activate T cells (4) , increased production of proinflammatory cytokines (5) , and prolonged cell survival (6, 7) . Interestingly, it was found that though RANK/RANKL interactions are important factors in the regulation of DC functions, lack of either molecule did not affect the development and distribution of peripheral DC (8, 9) . Normal ratios of various splenic DC subpopulations were observed as well as normal lymphocyte, platelet, granulocyte, and monocyte counts in peripheral blood. This was despite the osteopetrotic phenotype and may be explained by the extramedullary hematopoiesis observed in the liver of RANKL Ϫ/Ϫ mice (8) . In the skin, RANKL overexpression has been shown to promote LC activation and to control regulatory T cell homeostasis (10) . RANK has been shown to be up-regulated upon DC maturation and RANKL signaling from activated T lymphocytes provides a survival signal to some mature DC subtypes ensuring prolonged cellular interaction and induction of a sufficient immune response (11) . RANKL activity in vivo is regulated by a decoy receptor, osteoprotegerin (OPG, TNFRSF11b). Signaling through RANK engages TRAF-1, -2, -3, -5, and -6 and leads to the activation of several transcription factors such as NF-B, AP-1, ERK1/2, and NFAT. It has been associated with numerous physiological processes including organogenesis of lymph nodes and mammary glands (8, 9, 12) , bone homeostasis (13, 14) , and regulation of DC function (15, 16) .
Both RANKL and RANK have recently been shown to be expressed in breast (17) and thymic (18) epithelia and we, therefore, sought to determine their expression and function in human skin epidermis. We hypothesized that RANKL signaling might be of relevance to the extended longevity of LC in the skin and, being tightly intercalated between keratinocytes (KC), that KC may be a good source of such a LC sustaining signal.
Materials and Methods

Cell preparation
Skin biopsies were obtained after informed consent from patients undergoing breast reduction surgery or abdominoplasty. Epidermal sheets and epidermal single-cell suspensions were obtained as previously described (19, 20 progenitors were immunomagnetically isolated from umbilical cord blood and differentiated into LC-like DC (LCL-DC) as previously described (21) .
Phenotypic analysis
Expression of specific markers was determined using the following Abs from R&D Systems: RANKL (mAb6262) and RANK (mAb683), both detected by an Alexa-488-goat anti-mouse IgG (Invitrogen), mouse anti-human CD1a-APC (BD Pharmingen), and rat anti-mouse IA-IE PE (BD Pharmingen). For intracytoplasmic staining, cells were fixed in formaldehyde (2%) for 20 min before saponin (0.5%)-induced permeabilization. Apoptosis was detected by Annexin V-APC and propidium iodide (PI) staining (BD Pharmingen) or TUNEL (Roche) as indicated in the manufacturers' instructions. Specific binding was measured by flow cytometry on a FACSCalibur (BD Pharmingen) and analysis was performed using the WinMDI 2.8 software.
Immunofluorescence
Expression of specific markers was determined using the following Abs from R&D Systems: RANKL (mAb6262) and RANK (mAb683) detected by an Alexa-488-goat anti-mouse IgG (Invitrogen), mouse anti-human CD1a-PE (BD Pharmingen), and rat anti-mouse IA-IE PE (BD Pharmingen). Specific binding was detected by epifluorescent or confocal microscopy as indicated and images were created using Photoshop 7.0 software (Adobe).
In vitro induction and analysis of apoptosis
Following differentiation, LCL-DC were washed thoroughly and cultured for 48 h in 10% FCS RPMI 1640 supplemented as indicated with RANKL (50 ng/ml; PeproTech) and OPG (1 g/ml; PeproTech). Alternatively, cells were cultured for 7 days in GM-CSF (50 ng/ml; Schering-Plough), TGF-␤1 (4 ng/ml; R&D Systems), and TNF-␣ (10 ng/ml; R&D Systems) supplemented medium in the presence or absence of RANKL (50 ng/ml; PeproTech). Cells were collected and apoptosis determined by flow cytometry according to the manufacturer's protocol (Annexin V APC Apoptosis Detection kit; BD Pharmingen).
Animals
RANKL knockout (KO) mice (22) 
LC counts
Ears were collected from RANKL KO and normal wild-type (WT) littermate controls. Epidermal sheets were obtained as previously described (19) and were labeled with rat anti-mouse IA-IE-PE Ab (BD Pharmingen) (1/ 100 dilution) to detect LC. Samples were visualized by epifluorescent microscopy and images of six randomly chosen microscopic fields were acquired. LC were later enumerated in each image and mean values generated for each sheet.
BrdU incorporation
RANKL KO and WT littermate controls underwent in vivo BrdU labeling as previously described (23) . The 18-day-old mice were injected with 1 mg BrdU in saline per 20-g body weight i.p. and the litter given drinking water containing 0.8 mg/ml BrdU for 7 days. Mice were then sacrificed and whole body skin collected. The hair was removed using a thioglycolatebased hair removal cream (Veet) and the skin incubated overnight at 4°C in KC-adapted medium (CnT-57; CellnTec) containing 5 mg/ml dispase II (Roche). The epithelium was removed and incubated in trypsin (TrypLE Select; Invitrogen) for 20 min at 37°C. Cells were liberated by pipetting, filtered to remove epidermal fragments, washed in saline containing 0.2 mM EDTA and 2% FCS, and labeled for IA-IE (PE-conjugated mAb; eBioscience). Cells were then processed for BrdU detection according to the manufacturer's protocol (Flow BrdU detection kit; BD Pharmingen) with the modification that the Alexa 488-conjugated anti-Langerin mAb (clone 929F3; Dendritics) was added together with the APC-coupled antiBrdU mAb to the cells.
Ex vivo detection of apoptosis
Epidermal cell suspensions, generated by trypsin (Invitrogen) treatment of epidermal sheets obtained from ears as previously described (19) , were subjected to immunostaining for IA-IE expression and TUNEL according to the manufacturer's protocol (TUNEL Flow detection kit; ROCHE) and analyzed by flow cytometry.
Results
RANKL and RANK are constitutively expressed in normal human skin
RANKL and RANK expression was assessed by flow cytometry in epidermal single-cell suspensions obtained from normal human skin biopsies. Using this technique, basal KC can be distinguished from suprabasal KC according to their size and light FIGURE 1. RANKL and RANK are expressed in normal human skin. A, Intracellular and membrane-bound expression of RANKL in KC was assessed by flow cytometry. Basal and suprabasal KC populations were distinguished according to forward and side scatter characteristics, identified, respectively, as regions R1 and R2. Membrane-bound RANKL increased upon differentiation, whereas intracellular expression was detected in both subpopulations (specific binding (red histograms) is shown compared with isotype control staining (clear histograms)). B, RANKL expression in epidermis was assessed by immunofluorescence (green) and counterstained with nuclear dye TO-PRO-3 (blue). Expression was maximal in the suprabasal layers. C, Immunofluorescence for CD1a/RANK in epidermal sections and sheets. All CD1a ϩ LC expressed RANK. D, Membrane expression of RANK was assessed on epidermal LC by flow cytometry. Epidermal single-cell suspensions were subjected to Ficoll flotation to enrich for LC. RANK was expressed by all CD1a ϩ LC (R4, upper right quadrant). Each experiment is representative of more than three samples.
scatter parameters (24, 25) . Consistent with this, small low scatter cells express the basal-specific keratin 5, whereas larger cells associated with greater scatter were keratin 5 negative and keratin 10 positive, typical of suprabasal KC (data not shown). RANKL was clearly expressed by all KC (Fig. 1A) . Both basal and suprabasal KC expressed RANKL intracellularly, whereas suprabasal KC additionally expressed membrane bound RANKL. These findings were confirmed by immunofluorescent labeling of normal skin sections, which demonstrated RANKL expression throughout the epidermis with highest levels of expression in the suprabasal population.
Labeling of skin sections and epidermal sheet preparations with anti-RANK Abs demonstrated constitutive high level expression of RANK by LC in situ (Fig. 1C) . We additionally assessed LC surface expression of RANK by flow cytometry and observed that the vast majority (95.6 Ϯ 2.3%; n ϭ 3) of the CD1a ϩ (R2) population expressed membrane-bound RANK. RANK was moreover detected on the surface of a KC subpopulation (Fig. 1D) .
RANKL enhances in vitro-generated LC viability
RANKL signaling in mature DC has been associated with their survival. We, therefore, assessed whether RANKL/RANK interactions could sustain viability of immature LC obtained in vitro. Birbeck granule-positive, CD1a ϩ LCL-DC were generated from CD34
ϩ cord blood progenitors in the presence of GM-CSF and TGF-␤1 as previously described (21) . RANK expression by the LCL-DC population was confirmed ( Fig. 2A) . LCL-DC were cultured for an additional 48 h in complete medium deprived of cytokines and supplemented or not with RANKL in the presence or absence of OPG. Cellular viability was assessed after 48 h of culture by flow cytometry following Annexin V/PI staining (Fig. 2B) . Control LCL-DC cultured in cytokine free medium displayed rapid apoptosis with only half the cells alive after 72 h (55.2 Ϯ 5.7%; n ϭ 4). We found that RANKL stimulation induced a significant increase in survival (79.5 Ϯ 1% live cells; n ϭ 4; p Ͻ 0.05). Addition of OPG was able to significantly antagonize the action of RANKL (51.4 Ϯ 6.1% live cells; n ϭ 3; p Ͻ 0.05), whereas OPG alone was without effect (60.4 Ϯ 2.3% live cells; n ϭ 4; p Ͼ 0.05), suggesting that RANKL is not active in this system at a basal level (Fig. 2C) . Used in conjunction with other DC survival factors (GM-CSF, TGF-␤1, and TNF-␣), RANKL stimulation was also found to significantly increase cell survival ( p Ͻ 0.05) in 7 days cultures, above and over levels observed in the control, cytokine free, and supplemented (CS) media (cytokine free ϭ 19.5 Ϯ 4.6%; CS ϭ 42.5 Ϯ 5.9%; CS plus RANKL ϭ 61.9 Ϯ 5.3%; Mean viable cells; n ϭ 3) (Fig. 2D) . 
Mice deficient in RANKL display decreased LC numbers
To explore the role of RANKL in vivo, LC numbers in RANKL KO mice (22) and WT controls were compared. Epidermal sheets were obtained from mice deficient in RANKL and littermate controls and their LC enumerated in epidermal sheet preparations. Counts were taken from six randomly chosen sites in each ear and means calculated. RANKL KO mice displayed a 42% (n ϭ 9; p ϭ 0.0007) decrease in LC numbers (mean ϭ 507.1 Ϯ 77.2 per mm 2 ; n ϭ 9) compared with WT controls (mean ϭ 873.6 Ϯ 41.6 per mm 2 ; n ϭ 9) (Fig. 3A) . The morphology of the remaining LC appeared normal (Fig. 3B) .
RANKL KO show decreased LC proliferation
To determine the mechanism responsible for the reduction in LC numbers in RANKL-deficient mice, KO and control mice were exposed to the nucleotide analog BrdU and its incorporation in epidermal populations was analyzed by flow cytometry. To prevent the results from being influenced by the difference in BrdU incorporation observed in IA-IE Low/Ϫ KC, the studied population was restricted to IA-IE High /Langerin ϩ cells (Fig. 4A, gate R1) . In control mice, 38.26 Ϯ 4.6% (n ϭ 5) of LC had incorporated BrdU at 7 days and had, therefore, divided, in keeping with previous findings (26) . However, only 26.62 Ϯ 2.6% (n ϭ 4) of LC from KO animals were positive for BrdU, indicating significantly ( p Ͻ 0.02) decreased turnover (Fig. 4B) . Moreover, and in keeping with the observed decrease in LC numbers, the overall ratio of LC within epidermal suspensions was assessed and was found reduced in KO samples (WT ϭ 0.56 Ϯ 1.2% and KO ϭ 0.29 Ϯ 0.03%; n ϭ 4). Though the percentages of IA-IE Bright LC represents less than the usual 1-3% of LC found in epidermis, which may be explained by the lengthy treatment required to label for surface markers and nuclear BrdU simultaneously, both sample sets were treated identically, the comparison being, therefore, valid.
A decrease in LC numbers could also result from increased LC death in situ. We, therefore, assessed LC apoptosis by the TUNEL technique in freshly isolated epidermal cells. No significant difference was observed between WT controls and KO animals (Fig. 5 ).
Discussion
This study shows for the first time that the TNF superfamily molecule RANKL is a key regulator of epidermal LC proliferation and survival. There is close spatial apposition of cells expressing RANK and RANKL within epidermis, with KC expressing RANKL in a differentiation-dependent fashion and cell surface expression of RANK by all epidermal LC. Functionally, RANKL was able to sustain LC survival in vitro and mice deficient in RANKL had markedly reduced epidermal LC numbers as a consequence of a proliferation defect. It has previously been show that CD11c ϩ splenic DC populations did not suffer such disruptions in RANK-and RANKL-deficient mice (8, 9) . In this context, our data, therefore, highlight differences between the mechanisms and molecular signals that regulate the ontogeny and homeostasis of LC and other peripheral DC subtypes. Our study extends recent work that described expression of RANK and RANKL in human epidermis (10) . Our data clearly indicate that expression of RANKL is not uniform throughout the epidermis, but that maximal levels are present in the suprabasal compartment, precisely where LC reside. This echoes observations made in prostate epithelium where RANKL expression was found increased in luminal cells compared with basal cells (27) . The mechanism underlying this regulated expression is unidentified. However, the pattern of expression of RANKL closely mirrors that of the epidermal calcium gradient, a key determinant of RANKL expression (28 -30) and epidermal differentiation (31) .
Similarly to the effect observed on other DC subtypes, RANKL sustained the viability of immature LC in a short term in vitro model of apoptosis (induced by cytokine removal) and enhanced long term survival when added to CS medium (6) . Consistent with this, RANKL-deficient mice displayed a marked decrease in epidermal LC density, which appeared to be due to a defect in LC proliferation. Though no increase in LC apoptosis could be detected by TUNEL in RANKL-deficient epidermis, increased cell death cannot be excluded as cells may migrate out of epidermis before undergoing apoptosis. Interestingly, transgenic overexpression of RANKL expression in epidermis using a keratin 14 promoter system did not affect epidermal LC numbers (10) . This paradox may be explained by the supposition that the consequences of RANKL over-activity are carefully controlled in the epidermal microenvironment, either by regulation of cell surface expression of RANK, by increased production of OPG, or by changes in downstream signaling pathways. Moreover, we have recently shown that in other K14 transgenic mice, there is complex regulation of the consequences of transgene-driven secreted cytokine release (32) .
LC in the steady state have been shown to be long lived (23, 26, 33) in the epidermis and to renew in situ (26, 34) , though the molecular mechanisms involved have not yet been described. Our data suggest that KC-derived RANKL is a likely candidate for this role, although other factors cannot be ruled out. Such crosstalk between KC and LC has long been suspected, perhaps most notably in the regulation by IL-1, TNF, and IL-18 of LC migration from epidermis following contact with Ag (35) . In the dynamic context of inflammation, LC depletion, and epidermis repopulation, the mechanisms involved have been shown to differ from those involved in the steady-state maintenance of epidermal LC (34) . Though the investigation of a potential role for RANKL in this context would be of prime interest, such a study would need to overcome the technical challenges inherent to such long term experiments in short lived animals such as RANKL Ϫ/Ϫ mice. Pharmacological manipulation of RANKL/RANK interactions using recombinant OPG or peptide inhibitors is currently undergoing evaluation in the management of conditions such as osteoporosis (36) . Our data suggest that such manipulations may be accompanied by an effect on immunocytes in the skin, possibly with the consequence of decreasing epidermal LC longevity. Such an effect may well have useful therapeutic consequences in the treatment of inflammatory skin diseases. Unfortunately, the current resources of our laboratory did not allow us to pursue this further, and neither the reconstitution of RANKL in our system nor a pharmacological manipulation of RANKL levels in healthy animals could be attempted.
Our findings add to the increasing number of roles for RANKL in epithelial and DC biology. Although RANK expression is generally induced in DC following CD40L stimulation and maturation (4), immature CD14 ϩ dermal DC precursors have been shown to coexpress RANK and RANKL (7) . More recently, KC-derived RANKL was shown to regulate LC activation and UV-induced immunosuppression via an effect on regulatory T cell numbers (10) . Moreover, RANKL expression has been described in other epithelia, including mammary glands, lymph nodes, thymus, and thyroid (18, (37) (38) (39) , and its role in regulating DC homeostasis and function in these organs should be investigated.
